Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The development of new treatments for pancreatic cancer is set to be transformed by a network of pancreatic clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK announced today.

The investment will support the PRECISION Panc project which aims to develop personalised treatments for pancreatic cancer patients, improving the options and outcomes for a disease where survival rates have remained stubbornly low.

A team of researchers across the UK, including Dr Eric O’Neill of the CRUK/MRC Oxford Institute for Radiation Oncology in Oxford, aim to speed up recruitment and enrolment of pancreatic cancer patients to clinical trials that are right for the individual patient.

Dr Eric O'Neill commented: "The overall goal for PRECISION Panc is to personalise cancer treatment for pancreatic cancer based on the particular genomic background. Oxford's role is to assess whether radiotherapy offers a therapeutic advantage to molecularly targeted approaches for some of the more common pancreatic cancer subtypes. We will be working closely with our partners in PRECISION Panc to ensure findings are expedited into clinical trials to bring advantages to patients as soon as possible."

The researchers will use the molecular profile of each individual cancer to offer patients and their doctor a menu of trials that might benefit them. The first wave of research will establish the best way to collect and profile patient tissue samples. Each patient will have up to five samples taken from their tumour at diagnosis for analysis at the University of Glasgow. The results will guide clinical trial options in the future. The three trials planned as part of this initiative will recruit a total of 658 patients in 20 UK centres – with the scope to add more trials in the future. Patients will also be helped onto suitable clinical trials that are already up and running.

Professor Andrew Biankin, a Cancer Research UK pancreatic cancer expert at the University of Glasgow, said: “PRECISION Panc aims to transform how we treat pancreatic cancer by matching the right treatment to the right patient.  Because the disease is so aggressive, patients may receive no treatment at all or if they are given an option it will be for just one line of treatment, so it’s essential that the most suitable treatment is identified quickly. It’s important we offer all patients the opportunity to be part of research alongside their standard care.

The programme will ensure discoveries from the lab rapidly reach patients, and that data from clinical trials feed back into research of the disease. Cancer Research UK’s investment will support two of the three clinical trials, preclinical work, assay development, biomarker work and the huge amount of molecular sequencing. The charity’s funding will also provide overarching support though project management, funding staff, and a steering committee.

Professor Biankin added: “PRECISION Panc has been developed over the course of three years through the unwavering commitment of pancreatic clinicians and researchers who see that the patients deserve much more than is currently available to them. I’m fully committed to this project and I believe we’re on the cusp of making some incredible advances which will provide therapeutic options to help people affected this terrible disease. Without Cancer Research UK and their vision for cancer precision medicine, and the commitment of the other stakeholders, we couldn’t get PRECISION Panc up and running.

Dr Ian Walker, Cancer Research UK’s director of clinical research, said: “This ambitious project marks a new era for pancreatic cancer. Little progress has been made in outcomes for pancreatic cancer patients over the last 40 years, and we believe that PRECISION Panc will reshape how we approach treatment development. Cancer Research UK is determined to streamline research, to find the right clinical trial for all pancreatic cancer patients and to ensure laboratory discoveries have patient benefit.

Similar stories

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

OUH agrees long COVID research collaboration with Polarean

The collaboration will look at understanding the long-term effects of COVID-19 through cutting-edge MRI analysis.

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.